Royal Bank of Canada reiterated their outperform rating on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $32.00 price target on the stock.
EWTX has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price objective on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an overweight rating in a research report on Monday, August 12th. Wedbush reiterated an outperform rating and issued a $31.00 price target on shares of Edgewise Therapeutics in a report on Friday, August 16th. Finally, Piper Sandler restated an overweight rating and set a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of Buy and a consensus target price of $33.40.
View Our Latest Report on EWTX
Edgewise Therapeutics Price Performance
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. Equities analysts expect that Edgewise Therapeutics will post -1.48 earnings per share for the current year.
Hedge Funds Weigh In On Edgewise Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new stake in shares of Edgewise Therapeutics in the first quarter worth approximately $162,502,000. Novo Holdings A S bought a new stake in Edgewise Therapeutics during the second quarter worth $114,263,000. Baker BROS. Advisors LP raised its position in Edgewise Therapeutics by 87.6% in the 1st quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock valued at $106,523,000 after buying an additional 2,727,273 shares during the last quarter. Vanguard Group Inc. lifted its stake in Edgewise Therapeutics by 89.0% during the 1st quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock valued at $73,278,000 after acquiring an additional 1,892,053 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in Edgewise Therapeutics by 12.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,731,067 shares of the company’s stock worth $67,197,000 after acquiring an additional 427,500 shares during the last quarter.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
See Also
- Five stocks we like better than Edgewise Therapeutics
- Best Stocks Under $5.00
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 REITs to Buy and Hold for the Long Term
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.